Members from both UBC and Accredo recently attended NORD’s Rare Diseases and Orphan Products Breakthrough Summit in Arlington, VA. This was a great opportunity for leaders from both organizations to collaborate with key industry stakeholders to discuss the progress as well as challenges in rare disease diagnosis, clinical trials, patient engagement and access to orphan products.
Moving pharmaceutical products from development into commercialization is no small feat. Doing so for a rare disease and improving speed to therapy is even more challenging — but, because of UBC’s unique solutions and strategic partnerships, it’s a challenge that we can take on.
For rare-disease patients, a successful therapeutic journey is as unique as they are. Here is a look at some of the most pressing questions rare-disease patients face during their therapeutic journey.
The 50th DIA Annual Meeting, which kicks off today, promises to be a blast. We’re looking forward to presenting some unique abstracts and connecting with industry colleagues at our social event. But the highlight of the event for our team is the chance to have fun while helping patients in a unique way.
Today kicks off the 23rd annual Partnerships in Clinical Trials (PCT) conference where we’re looking forward to connecting with many of our industry colleagues, having a little fun, and taking time to give back.